Business Description
Mendus AB
NAICS : 325412
SIC : 2834
ISIN : SE0005003654
Compare
Compare
Traded in other countries / regions
IMMU.Sweden1YG.GermanyIMMUs.UK IPO Date
2013-04-22Description
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.64 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.24 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 42 | |||||
| 3-Year EPS without NRI Growth Rate | 41 | |||||
| 3-Year FCF Growth Rate | 19.8 | |||||
| 3-Year Book Growth Rate | -39.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.06 | |||||
| 9-Day RSI | 54.96 | |||||
| 14-Day RSI | 51.79 | |||||
| 6-1 Month Momentum % | -11.71 | |||||
| 12-1 Month Momentum % | -58.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.24 | |||||
| Quick Ratio | 7.24 | |||||
| Cash Ratio | 4.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -68.5 | |||||
| Shareholder Yield % | -66.59 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -17.26 | |||||
| ROA % | -15.32 | |||||
| ROIC % | -20.7 | |||||
| ROC (Joel Greenblatt) % | -231.68 | |||||
| ROCE % | -16.05 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.6 | |||||
| Price-to-Tangible-Book | 2.91 | |||||
| EV-to-EBIT | -4.11 | |||||
| EV-to-EBITDA | -4.32 | |||||
| EV-to-Forward-EBITDA | -3.5 | |||||
| EV-to-Forward-Revenue | 135.35 | |||||
| EV-to-FCF | -3 | |||||
| Price-to-Net-Current-Asset-Value | 3.88 | |||||
| Price-to-Net-Cash | 9.31 | |||||
| Earnings Yield (Greenblatt) % | -24.31 | |||||
| FCF Yield % | -29.89 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mendus AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.156 | ||
| Beta | 0.86 | ||
| Volatility % | 94.43 | ||
| 14-Day RSI | 51.79 | ||
| 14-Day ATR (kr) | 0.027819 | ||
| 20-Day SMA (kr) | 0.466775 | ||
| 12-1 Month Momentum % | -58.76 | ||
| 52-Week Range (kr) | 0.3 - 1.470031 | ||
| Shares Outstanding (Mil) | 1,007.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mendus AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mendus AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mendus AB Frequently Asked Questions
What is Mendus AB(OSTO:IMMU)'s stock price today?
The current price of OSTO:IMMU is kr0.47. The 52 week high of OSTO:IMMU is kr1.47 and 52 week low is kr0.30.
When is next earnings date of Mendus AB(OSTO:IMMU)?
The next earnings date of Mendus AB(OSTO:IMMU) is 2024-08-23.
Does Mendus AB(OSTO:IMMU) pay dividends? If so, how much?
Mendus AB(OSTO:IMMU) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers